WallStreetZenWallStreetZen

NASDAQ: ORTX
Orchard Therapeutics PLC Stock

$16.22+0.00 (+0%)
Updated Dec 5, 2023
ORTX Price
$16.22
Fair Value Price
$449.81
Market Cap
$369.18M
52 Week Low
$3.60
52 Week High
$16.30
P/E
-4.06x
P/B
4.6x
P/S
8.08x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.84M
Earnings
-$72.92M
Gross Margin
69.2%
Operating Margin
-317.16%
Profit Margin
-333.9%
Debt to Equity
1.52
Operating Cash Flow
-$93M
Beta
0.65
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ORTX Overview

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ORTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ORTX ($16.22) is undervalued by 96.39% relative to our estimate of its Fair Value price of $449.81 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ORTX ($16.22) is significantly undervalued by 96.39% relative to our estimate of its Fair Value price of $449.81 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ORTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ORTX due diligence checks available for Premium users.

Be the first to know about important ORTX news, forecast changes, insider trades & much more!

ORTX News

Valuation

ORTX fair value

Fair Value of ORTX stock based on Discounted Cash Flow (DCF)
Price
$16.22
Fair Value
$449.81
Undervalued by
96.39%
ORTX ($16.22) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ORTX ($16.22) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ORTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ORTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.06x
Industry
11.32x
Market
30.4x

ORTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.6x
Industry
5.44x
ORTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ORTX's financial health

Profit margin

Revenue
$6.3M
Net Income
-$35.3M
Profit Margin
-560.4%
ORTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ORTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$202.3M
Liabilities
$122.0M
Debt to equity
1.52
ORTX's short-term assets ($153.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ORTX's short-term assets ($153.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ORTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$23.9M
Investing
$11.6M
Financing
-$2.4M
ORTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ORTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ORTX$369.18M0.00%-4.06x4.60x
NAUT$364.84M-0.34%-6.08x1.32x
NRIX$373.96M+2.66%-2.81x1.60x
CELC$363.05M-0.13%-5.49x3.91x
IGMS$375.47M+9.17%-1.29x1.48x

Orchard Therapeutics Stock FAQ

What is Orchard Therapeutics's quote symbol?

(NASDAQ: ORTX) Orchard Therapeutics trades on the NASDAQ under the ticker symbol ORTX. Orchard Therapeutics stock quotes can also be displayed as NASDAQ: ORTX.

If you're new to stock investing, here's how to buy Orchard Therapeutics stock.

What is the 52 week high and low for Orchard Therapeutics (NASDAQ: ORTX)?

(NASDAQ: ORTX) Orchard Therapeutics's 52-week high was $16.30, and its 52-week low was $3.60. It is currently -0.49% from its 52-week high and 350.43% from its 52-week low.

How much is Orchard Therapeutics stock worth today?

(NASDAQ: ORTX) Orchard Therapeutics currently has 227,610,439 outstanding shares. With Orchard Therapeutics stock trading at $16.22 per share, the total value of Orchard Therapeutics stock (market capitalization) is $369.18M.

Orchard Therapeutics stock was originally listed at a price of $140.00 in Oct 31, 2018. If you had invested in Orchard Therapeutics stock at $140.00, your return over the last 5 years would have been -88.41%, for an annualized return of -35.02% (not including any dividends or dividend reinvestments).

How much is Orchard Therapeutics's stock price per share?

(NASDAQ: ORTX) Orchard Therapeutics stock price per share is $16.22 today (as of Dec 5, 2023).

What is Orchard Therapeutics's Market Cap?

(NASDAQ: ORTX) Orchard Therapeutics's market cap is $369.18M, as of Dec 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Orchard Therapeutics's market cap is calculated by multiplying ORTX's current stock price of $16.22 by ORTX's total outstanding shares of 227,610,439.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.